Effect of Erythropoietin in Refractory Autoimmune Encephalitis Patients
NCT ID: NCT03004209
Last Updated: 2021-09-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE4
INTERVENTIONAL
2016-12-31
2018-02-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Multicenter and Prospective Clinical Registry Study of Autoimmune Encephalitis in China
NCT02561260
A Multicentric Cohort of Autoimmune Encephalitis
NCT06760091
Diffusion Imaging in Acute Auto-immune Encephalitis
NCT04339205
Risk Prediction Model for Severe Autoimmune Encephalitis
NCT06697678
To Explore Cognitive Neural Mechanism of Autoimmune Encephalitis by Using Neuropsychological Tests and Multi-modal MRI
NCT03530462
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
We expect that erythropoietin may lead to improve the symptoms and outcome of autoimmune encephalitis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
EPO
Erythropoietin injection: three times per a week, 100 IU/kg for each patients Trade name: epokine prefilled injection
Erythropoietin
three times per a week 100IU / k
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Erythropoietin
three times per a week 100IU / k
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ineffective 1st line treatment (e.g. steroid IV, IVIg) and 2nd line treatment (e.g. Rituximab or cyclophosphamide)
Exclusion Criteria
* Hematochrit \>36%
* Thrombocytosis \> 750K
* AST or ALT \> 120
* HIV (+)
* Allergic reaction upon erythropoietin
* Uncontrolled hypertension
* mRS before the autoimmune encephalitis \> 3
* Breast feeding or pregnancy
* History of ischemic stroke or pulmonary thrombosis
* Refuse to be enrolled
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Seoul National University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kon Chu
Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kon Chu, Ph.D
Role: PRINCIPAL_INVESTIGATOR
Seoul National University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Seoul National University Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1607-120-777
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.